ENDLOS-TURBO CALL - ELI LILLY & CO | Delayed Deutsche Boerse AG 09:04:41 27/06/2024 BST | ||
| 49.38 EUR | +0.22% |
|
| Current month | +20.94% | ||
| 1 month | +22.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 49.38 | +0.22% |
| 26/06/24 | 49.27 | +0.18% |
| 25/06/24 | 49.18 | +1.99% |
| 24/06/24 | 48.22 | +1.17% |
| 21/06/24 | 47.66 | +0.46% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 09:04 am
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | DZ BANK |
| WKN | DJ0ZNA |
| ISIN | DE000DJ0ZNA5 |
| Date issued | 05/04/2023 |
| Strike | 375.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.1 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 50 € |
|---|---|
| Lowest since issue | 1.2 € |
| Spread | 0.18 € |
| Spread % | 0.36% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
